Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | WNT1 | P04628 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.31 |
| ▸ | BACE1 | P56817 | 3/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913365 | 1.00 | GSK3B (0.32) | GSK3BDYRK1AWNT1IRAK4CDK2 | |
| SCHEMBL20927009 | 0.89 | STK17B (0.36) | GSK3BDYRK1AIRAK4CDK2BACE1 | |
| SCHEMBL20927013 | 0.89 | STK17B (0.36) | GSK3BDYRK1AIRAK4CDK2BACE1 | |
| SCHEMBL20913362 | 0.86 | TP53 (0.33) | CDK2P2RX7CCNA2 | |
| SCHEMBL20959598 | 0.83 | WNT1 (0.34) | GSK3BDYRK1AWNT1IRAK4APP | |
| SCHEMBL20959593 | 0.83 | WNT1 (0.34) | GSK3BDYRK1AWNT1IRAK4APP | |
| SCHEMBL16076738 | 0.76 | STK17B (0.39) | GSK3BDYRK1AP2RX7TTK | |
| SCHEMBL30926288 | 0.76 | STK17B (0.39) | GSK3BDYRK1AP2RX7TTK | |
| SCHEMBL20926953 | 0.75 | STK17B (0.38) | GSK3BDYRK1ATTK | |
| SCHEMBL20913345 | 0.72 | TP53 (0.35) | CDK2P2RX7CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858835-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | GSK3B 2324/4885DYRK1A 1245/4885WNT1 523/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | GSK3B 1634/4885DYRK1A 1586/4885WNT1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.